Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Faecal Microbiota Transplantation in Clinical Practice
share announcement

Faecal Microbiota Transplantation in Clinical Practice

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 2850

Special Issue Editors

Dr. Chaysavanh Manichanh

E-Mail Website
Guest Editor
Research Director, Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain
Interests: microbiome; metaomics techniques; fecal microbiota transplantation; inflammatory bowel disease; irritable bowel syndrome; liver diseases
Dr. Severine Vermeire

grade E-Mail Website
Guest Editor
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
Interests: inflammatory bowel diseases; ulcerative colitis; crohn’s disease; therapy; microbiome; fecal microbiota transplantation

Special Issue Information

Dear Colleagues,

Fecal microbiota transplantation (FMT) has the potential to restore a perturbed gut microbial ecosystem, as it has been demonstrated by the efficient treatment of Clostridioides difficile infections (CDI). However, the efficiency of FMT is low for other intestinal or extra-intestinal diseases of very high incidence, as it is a case of inflammatory bowel disorders (IBD). This inefficacy could be explained, in part, by the multifactorial nature of IBD, which can develop with a genetic predisposition towards pro-inflammatory immune responses and intestinal barrier dysfunction. Therefore, we need a better understanding of the mechanisms underlying the crosstalk between recipient and donor microbiota. Moreover, a more comprehensive donor screening is also needed to prevent the transmission of microorganisms such as the extended spectrum beta-lactamase (ESBL)-producing E. coli and the SARS-Cov-2 that could lead to adverse infectious events. It is therefore crucial to establish consensus in terms of the route of administration, pre-treatment of recipients, or selection and testing of donor stool among other considerations.

In this Special Issue, "Fecal Microbiota Transplantation in Clinical Practice ", submission of original papers or review articles are welcomed.

Dr. Chaysavanh Manichanh
Dr. Severine Vermeire
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Intestinal and extra-intestinal disorders
  • Randomized controlled trials
  • Donor sample screening and testing
  • Recipient stratification
  • Recipient pre-treatment
  • Preparation of fecal material
  • Route of administration
  • Long-term monitoring of patients
  • Feces biobanking
  • Requirements for implementing an FMT center

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 818 KiB  
Article
Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI?
by Daniel Popa, Bogdan Neamtu, Manuela Mihalache, Adrian Boicean, Adela Banciu, Daniel Dumitru Banciu, Doru Florian Cornel Moga and Victoria Birlutiu
J. Clin. Med. 2021, 10(24), 5822; https://doi.org/10.3390/jcm10245822 - 13 Dec 2021
Cited by 13 | Viewed by 2369
Abstract
Background: Faecal microbiota transplant (FMT) is a highly effective therapy for recurrent Clostridioides difficile infection (rCDI) with cure rates ranging between 85 and 92%. The FMT role for primary Clostridioides difficile infection (CDI) has yet to be settled because of limited data and [...] Read more.
Background: Faecal microbiota transplant (FMT) is a highly effective therapy for recurrent Clostridioides difficile infection (rCDI) with cure rates ranging between 85 and 92%. The FMT role for primary Clostridioides difficile infection (CDI) has yet to be settled because of limited data and small-sample studies presented in the current literature. Our study goals were to report the risk factors and the risk of recurrence after FMT for each CDI episode (first, second, and third) and to explore if there is a role of FMT in primary severe CDI. Methods: We conducted a retrospective study to analyze the clinical characteristics and the outcomes of 96 FMT patients with a prior 10 day course of antibiotic treatment in the medical records, of which 71 patients with recurrent CDI and 25 patients with a primary CDI. Results: The overall primary cure rate in our study was 88.5% and the primary cure rate for the severe forms was 85.7%. The data analysis revealed 5.25%, 15.15%, and 27.3% FMT recurrence rates for primary, secondary, and tertiary severe CDI. The risk of recurrence was significantly associated with FMT after the second and the third CDI severe episodes (p < 0.05), but not with FMT after the first severe CDI episode. Conclusions: This study brings new data in supporting the FMT role in CDI treatment, including the primary severe CDI, however, further prospective and controlled studies on larger cohorts should be performed in this respect. Full article
(This article belongs to the Special Issue Faecal Microbiota Transplantation in Clinical Practice)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop